138 related articles for article (PubMed ID: 26304880)
1. Bevacizumab Plus Chemotherapy Cost Effectiveness.
Bordonaro R; Cordio S; Uccello M; Martines C; Fassari GE
J Clin Oncol; 2015 Nov; 33(32):3840-1. PubMed ID: 26304880
[No Abstract] [Full Text] [Related]
2. Effectiveness and Cost Effectiveness of Bevacizumab in Metastatic Colorectal Cancer.
Messori A; De Rosa M; Fadda V; Pani L
J Clin Oncol; 2015 Nov; 33(32):3838-9. PubMed ID: 26304897
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
4. Costs of chemotherapy in the treatment of colorectal cancer.
Jansman FG; Postma MJ
Eur J Health Econ; 2006 Jun; 7(2):145-6. PubMed ID: 16699776
[No Abstract] [Full Text] [Related]
5. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
J Clin Oncol; 2015 Apr; 33(10):1112-8. PubMed ID: 25691669
[TBL] [Abstract][Full Text] [Related]
6. [Cost effectiveness analysis of two adjuvant regimens in the treatment of colorectal cancer: an interpretation of the MOSAIC Study].
Rebesco B; Cantagalli E; Amalfitano ME
Tumori; 2005; 91(6):suppl 1-10. PubMed ID: 16457161
[No Abstract] [Full Text] [Related]
7. Cost-effectiveness analysis of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Graham CN; Hechmati G; Hjelmgren J; de Liège F; Lanier J; Knox H; Barber B
Eur J Cancer; 2014 Nov; 50(16):2791-801. PubMed ID: 25219451
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales.
Tappenden P; Jones R; Paisley S; Carroll C
Eur J Cancer; 2007 Nov; 43(17):2487-94. PubMed ID: 17910914
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
[TBL] [Abstract][Full Text] [Related]
10. Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer.
Ruiz-Millo O; Albert-Mari A; Sendra-Garcia A; Jimenez-Torres NV
J Oncol Pharm Pract; 2014 Oct; 20(5):341-50. PubMed ID: 24177355
[TBL] [Abstract][Full Text] [Related]
11. Can money really be no object when cancer care is the subject?
Saltz LB
J Clin Oncol; 2015 Apr; 33(10):1093-4. PubMed ID: 25691668
[No Abstract] [Full Text] [Related]
12. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
Whyte S; Pandor A; Stevenson M; Rees A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
[TBL] [Abstract][Full Text] [Related]
13. Balancing Clinical Progress With Economic Sustainability: In Quest of a Courageous Solution.
Fasola G; Aprile G; Pinto C
J Clin Oncol; 2015 Nov; 33(32):3841-2. PubMed ID: 26304899
[No Abstract] [Full Text] [Related]
14. ["The expensive" health care. Sneaky rationing or ration book?!].
Breimer L
Lakartidningen; 2015 Apr; 112():. PubMed ID: 25898381
[No Abstract] [Full Text] [Related]
15. [The debate on ethics, law and new expensive drugs. Speak clearly about health care limitations].
Bratt O
Lakartidningen; 2015 Jun; 112():. PubMed ID: 26126014
[No Abstract] [Full Text] [Related]
16. The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.
Carter HE; Zannino D; John Simes R; Schofield DJ; Howard K; Zalcberg JR; Price TJ; Tebbutt NC
Eur J Cancer; 2014 Feb; 50(3):535-43. PubMed ID: 24215848
[TBL] [Abstract][Full Text] [Related]
17. Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al.
Saltz LB
J Clin Oncol; 2015 Nov; 33(32):3843-4. PubMed ID: 26304894
[No Abstract] [Full Text] [Related]
18. Reply to A. Messori et al, R. Bordonaro et al, and G. Fasola et al.
Goldstein DA; El-Rayes BF; Chen Q; Flowers CR
J Clin Oncol; 2015 Nov; 33(32):3842-3. PubMed ID: 26304876
[No Abstract] [Full Text] [Related]
19. Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
Goldstein DA; El-Rayes BF
Oncologist; 2015 Sep; 20(9):981-2. PubMed ID: 26265225
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab as First-line Treatment for Metastatic Colorectal Cancer: Caution With Interpretation of Cost-Effectiveness Results Toward Medical Decision Making.
Franken MD; Koopman M; van Oijen MG
Am J Clin Oncol; 2016 Apr; 39(2):214. PubMed ID: 26999056
[No Abstract] [Full Text] [Related]
[Next] [New Search]
